6.
Sapru M, Yates J, Hogan S, Jiang L, Halter J, Bohn M
. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp Neurol. 2006; 198(2):382-90.
DOI: 10.1016/j.expneurol.2005.12.024.
View
7.
Zharikov A, Bai Q, De Miranda B, Van Laar A, Greenamyre J, Burton E
. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiol Dis. 2019; 125:146-153.
PMC: 6440542.
DOI: 10.1016/j.nbd.2019.01.004.
View
8.
Chen M, Vincent J, Ezeanii A, Wakade S, Yerigenahally S, Mor D
. Heparan sulfate proteoglycans mediate prion-like α-synuclein toxicity in Parkinson's in vivo models. Life Sci Alliance. 2022; 5(11).
PMC: 9259873.
DOI: 10.26508/lsa.202201366.
View
9.
Hmila I, Vaikath N, Majbour N, Erskine D, Sudhakaran I, Gupta V
. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy-body pathology and inhibit in-vitro seeded aggregation and toxicity. FEBS J. 2022; 289(15):4657-4673.
PMC: 9545584.
DOI: 10.1111/febs.16376.
View
10.
Vargas J, Grudina C, Zurzolo C
. The prion-like spreading of α-synuclein: From in vitro to in vivo models of Parkinson's disease. Ageing Res Rev. 2019; 50:89-101.
DOI: 10.1016/j.arr.2019.01.012.
View
11.
Parres-Gold J, Chieng A, Wong Su S, Wang Y
. Real-Time Characterization of Cell Membrane Disruption by α-Synuclein Oligomers in Live SH-SY5Y Neuroblastoma Cells. ACS Chem Neurosci. 2020; 11(17):2528-2534.
PMC: 7484231.
DOI: 10.1021/acschemneuro.0c00309.
View
12.
Bernis M, Babila J, Breid S, Wusten K, Wullner U, Tamguney G
. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun. 2015; 3:75.
PMC: 4660655.
DOI: 10.1186/s40478-015-0254-7.
View
13.
Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro T, Pepivani I
. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol. 2008; 213(2):315-25.
DOI: 10.1016/j.expneurol.2008.06.004.
View
14.
Volc D, Poewe W, Kutzelnigg A, Luhrs P, Thun-Hohenstein C, Schneeberger A
. Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020; 19(7):591-600.
DOI: 10.1016/S1474-4422(20)30136-8.
View
15.
Moreno P, Fexova S, George N, Manning J, Miao Z, Mohammed S
. Expression Atlas update: gene and protein expression in multiple species. Nucleic Acids Res. 2021; 50(D1):D129-D140.
PMC: 8728300.
DOI: 10.1093/nar/gkab1030.
View
16.
Nascimento A, Erustes A, Reckziegel P, Bincoletto C, Ureshino R, Pereira G
. α-Synuclein Overexpression Induces Lysosomal Dysfunction and Autophagy Impairment in Human Neuroblastoma SH-SY5Y. Neurochem Res. 2020; 45(11):2749-2761.
DOI: 10.1007/s11064-020-03126-8.
View
17.
Lee J, Takahama S, Zhang G, Tomarev S, Ye Y
. Unconventional secretion of misfolded proteins promotes adaptation to proteasome dysfunction in mammalian cells. Nat Cell Biol. 2016; 18(7):765-76.
PMC: 10701763.
DOI: 10.1038/ncb3372.
View
18.
Huo J, Wang Y, Fu W, Lu N, Liu Z
. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. Front Immunol. 2022; 13:956090.
PMC: 9361790.
DOI: 10.3389/fimmu.2022.956090.
View
19.
Naran K, Nundalall T, Chetty S, Barth S
. Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Front Microbiol. 2019; 9:3158.
PMC: 6308495.
DOI: 10.3389/fmicb.2018.03158.
View
20.
Horsager J, Andersen K, Knudsen K, Skjaerbaek C, Fedorova T, Okkels N
. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain. 2020; 143(10):3077-3088.
DOI: 10.1093/brain/awaa238.
View